A dose-response relationship was identified between disordered eating and non-medical use, where risk for non-medical use increased with the number of disordered eating attitudes and behaviors reported. CONCLUSIONS The risk for NMUPS increases with disordered eating symptomatology. There is a need to assess for NMUPS among college students presenting with disordered eating. BACKGROUND Chronic non-cancer pain (CNCP) among patients with substance use disorder (SUD) poses a risk for worse treatment outcomes. Understanding the association of CNCP with SUD is important for informing the need and potential benefits of pain assessment/management among those with SUDs. METHODS We analyzed electronic health record data from 2013 to 2018 among adults aged ?18 years (N?=?951,533; mean age 48.4 years; 57.4 % female) in a large academic healthcare system. Adjusted logistic regression models were conducted to estimate the association of CNCP conditions with opioid overdose, emergency department utilization, and inpatient hospitalization stratified by different SUD diagnoses and by gender. RESULTS Among the total sample, the prevalence of CNCP was 46.6 % and any SUD was 11.2 %. The majority of patients with a SUD had CNCP (opioid 74.7 %; sedative 72.3 %; cannabis 64.3 %; alcohol 58.7 %; tobacco 59.5 %). The prevalence of CNCP was greater in females vs. males for most SUD diagnoses. The presence of CNCP was associated with more mental health disorders and chronic medical conditions among each SUD group. CNCP was associated with significantly decreased odds of overdose among those with opioid use disorder but increased odds of overdose and healthcare utilization among other SUDs. https://www.selleckchem.com/products/lusutrombopag.html CNCP was positively associated with overdose in females, but not males, with alcohol or non-opioid drug use disorders. CONCLUSIONS The direction and magnitude of the association between CNCP and negative health indicators differed as a function of SUD type and gender, respectively. Greater awareness of potential unmet pain treatment need may have implications for improving SUD outcomes. Since time immemorial, humans have tried to feign physical and mental illnesses for various reasons. This led to the development of the concept of illness deception or malingering when one tries to assume a sick role and feigns signs and symptoms to gain external incentives. The conceptual framework of malingering has undergone several changes and there is sufficient evidence to demonstrate that malingering exists. However, the diagnosis of malingering has not yet been established in the mainstream psychiatric nosological systems and still it is present in the appendices as an additional area requiring attention. This is due to the poor construct validity of the diagnosis, problems in defining malingering, problems in assessment by psychological tests and clinical assessment methodology, no well-established guidelines to detect malingering and issues related to labelling/reporting malingering. Because of several controversies in multiple domains of assessment and ethical-social issues, malingering as a distinct entity is grossly neglected. In the upcoming arena of law suits and consumer benefits suits, it is extremely important to have a better understanding of the conceptual issues related to malingering and the controversies related to it. In this review, a brief overview of evolution of concepts and controversies related to malingering is described. The Global Burden of Epilepsy Report estimates that there are 13 million disability adjusted life years due to epilepsy each year. Estimates of years lived with disability attributed to uncontrolled and untreated epilepsies are particularly raised in comparison to controlled epilepsies in countries with low sociodemographic indices. There are 50 million people with epilepsy in the world and of these, 125,000 die each year, and over 80% of these deaths occur in low- and middle-income countries. Overall, a global decline in the number of epilepsy-related deaths has been seen between 1990 and 2016. The least improvements have been, however, recorded in countries with low sociodemographic indices. These countries include 13 African countries, which have recorded an increase in number of epilepsy deaths over the 26?years. The huge burden of untreated and uncontrolled epilepsy and of epilepsy-related deaths in low- and middle-income countries calls for urgent efforts to improve access to epilepsy management. This investigation examined age-related differences in neck muscle activation latency in response to anterior and posterior postural perturbations to understand the potential implications in fall-related traumatic brain injuries. 57 adults were recruited and categorized into 3 groups based on age Young (18-30&nbsp;years old), Young-Old (60-74&nbsp;years) and Old-Old (75-89&nbsp;years) group. Study participants underwent six anterior and posterior postural perturbations while bilateral sternocleidomastoid, upper trapezius, and splenius capitis electromyography was collected. Muscle activation latency time was calculated with established procedures. During anterior translations, a significant group effect for muscle activation latency of the right SCM (F(2,43)&nbsp;=&nbsp;8.786, p&nbsp; less then &nbsp;0.001), right (F(2,34)&nbsp;=&nbsp;4.838, p&nbsp;=&nbsp;0.014) and left (F(2,34)&nbsp;=&nbsp;5.015, p&nbsp;=&nbsp;0.012) upper trapezius, and right (F(2,45)&nbsp;=&nbsp;3.195, p&nbsp;=&nbsp;0.050) and left (F(2,45)&nbsp;=&nbsp;3.819, p&nbsp;=&nbsp;0.029) splenius capitis was observed. During posterior translations, a significant group effect for muscle activation latency was observed in the right (F(2,34)&nbsp;=&nbsp;6.419, p&nbsp;=&nbsp;0.004) and left (F(2,41)&nbsp;=&nbsp;5.275, p&nbsp;=&nbsp;0.009) SCM, and the right (F(2,34)&nbsp;=&nbsp;4.925, p&nbsp;=&nbsp;0.013) and left (F(2,32)&nbsp;=&nbsp;4.055, p&nbsp;=&nbsp;0.027) upper trapezius. Both older groups displayed longer muscle activation latencies than the young group. The age-related differences in neck muscle activation latency may be placing older adults at a greater risk of fall-related traumatic brain injuries. Clostridioides difficile is the leading cause of hospital-acquired gastrointestinal infections and a major public health burden in the United States. C. difficile infection causes a spectrum of disease from mild diarrhea to severe complications such as pseudomembranous colitis, toxic megacolon and death. This broad range of disease is only partially explained by bacterial genetic factors, host genetics, comorbidities and previous drug exposures. Another important factor is the gut microbiome, the disruption of which results in a loss of colonization resistance to C. difficile. Here, we review how gut microbiota and their metabolites impact C. difficile virulence and influence disease.